ClinicalTrials.gg
CompletedNCT02735603Updated Nov 1, 2016

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

A Phase 1 interventional study of Naltrexone HCl/bupropion HCl and Placebo in Heart Repolarization, sponsored by Orexigen Therapeutics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-01.

Sponsored by Orexigen Therapeutics, Inc · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the potential effect of naltrexone and bupropion extended-release combination on cardiac repolarization in healthy participants.

Read the detailed description

The drug being tested in this study is called naltrexone HCl/bupropion HCl (NB). NB is approved by the U.S. Food and Drug Administration (FDA) in addition to a reduced-calorie diet and increased physical activity for chronic weight management in adults who are obese or who are overweight and have at least one additional weight-related condition such as high blood pressure, diabetes or high cholesterol. This study is conducted to determine the potential effect of NB relative to placebo on cardiac repolarization.

The study will enroll approximately 84 participants. Participants will be randomly assigned (by chance, like flipping a coin) to 1 of 6 treatment sequences, which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Naltrexone/Bupropion + Placebo + Moxifloxacin
  • Placebo + Moxifloxacin + Naltrexone/Bupropion
  • Moxifloxacin + Naltrexone/Bupropion + Placebo
  • Naltrexone/Bupropion + Moxifloxacin + Placebo
  • Placebo + Naltrexone/Bupropion + Moxifloxacin
  • Moxifloxacin + Placebo + Naltrexone/Bupropion

This study is consisted of 3 periods separated by a washout period (Days 11 through 25). Participants will be admitted to the clinic on Day -2 (Check-in) of each study period and will remain confined to the clinic until the morning of Day 12 of each study period. On Day -1 and Day 11 of each period, participants will undergo 24 hour Holter recordings using an ambulatory electrocardiograph recorder.

This single center trial will be conducted in the United States. The overall time to participate in this study is approximately 96 days.

02

Conditions studied

  • Heart Repolarization
03

In context

Lead sponsor

Orexigen Therapeutics, Inc is the lead sponsor of 18 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a healthy male or female.
  2. Is aged 18 to 55 years, inclusive, at signing of and first dose of study drug.
  3. Weighs at least 50 kilogram (kg) and has a (BMI) of 18.0 to 35.0 kilogram per square meter (kg/m\^2), inclusive, at screening.

Exclusion criteria

Exclusion Criteria:

  1. Has known to moxifloxacin or other quinolone antibiotics or any component of the formulation of naltrexone/bupropion.
  2. Has a history of seizure of any etiology, or of predisposition to seizures.
  3. Has a history of significant cardiac disease.
  4. Has a history of bulimia.
  5. Has a history of anorexia nervosa.
  6. Has a concentration less than (\<) 12 gram per deciliter (g/dL) at screening or check-in (day -2) of period 1.
  7. Has resting heart rate outside the normal range of 45 to 100 beats per minute at screening or check-in (day -2) of period 1.
  8. Has orthostatic blood pressure greater than or equal to (>=) 25 millimeters of mercury (mm Hg) at screening or check-in (day -2) of period 1.
  9. Has sustained supine systolic blood pressure >=140 mm Hg or \<=90 mm Hg or a diastolic blood pressure >=90 mm Hg or \<=50 mm Hg at screening or check-in (day -2) of period 1.
  10. Has abnormal screening or check-in (day -2) of period 1 indicating a second- or third-degree atrioventricular block, or 1 or more of the following: PR >220 msec, QRS >120 msec, and >450 msec, or any rhythm other than sinus rhythm that is interpreted by the investigator to be or could interfere with an accurate measurement of the QT interval.
  11. Has family history of long QT syndrome.
  12. Had extensive exercising in normal life, for example, marathon running, triathlon, physical sports at a contest level.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Nalterxone/Bupropion + Placebo + Moxifloxacin

    Naltrexone hydrochloride (HCl) 8 milligram (mg)/bupropion HCl 90 mg (NB) placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.

    Drug: Naltrexone HCl/bupropion HCl · Other: Placebo · Drug: Moxifloxacin

  • Experimental
    Placebo + Moxifloxacin + Naltrexone/Bupropion

    NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.

    Drug: Naltrexone HCl/bupropion HCl · Other: Placebo · Drug: Moxifloxacin

  • Experimental
    Moxifloxacin + Naltrexone/Bupropion + Placebo

    NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Day 4 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in the treatment period 3.

    Drug: Naltrexone HCl/bupropion HCl · Other: Placebo · Drug: Moxifloxacin

  • Experimental
    Naltrexone/Bupropion + Moxifloxacin + Placebo

    NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 3.

    Drug: Naltrexone HCl/bupropion HCl · Other: Placebo · Drug: Moxifloxacin

  • Experimental
    Placebo + Naltrexone/Bupropion + Moxifloxacin

    NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.

    Drug: Naltrexone HCl/bupropion HCl · Other: Placebo · Drug: Moxifloxacin

  • Experimental
    Moxifloxacin + Placebo + Naltrexone/Bupropion

    NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.

    Drug: Naltrexone HCl/bupropion HCl · Other: Placebo · Drug: Moxifloxacin

Interventions

  • DrugNaltrexone HCl/bupropion HCl

    Drug pages: Naltrexone · Bupropion

    Naltrexone HCl/bupropion HCl extended-release tablet.

  • OtherPlacebo

    Naltrexone/bupropion placebo-matching tablets.

  • Moxifloxacin tablet.

06

What researchers measure

Primary outcomes

  1. The time-matched change from Baseline in QT interval with Fridericia correction method (QTcF)

    QT and RR intervals will be recorded using ECG machines. Fridericia correction method is calculated by dividing QT interval by the cube root of the RR interval: QTcF = QT/RR\^1/3.

    Time frame: Time matched Baseline and Day 11 within 30 minutes predose and up to 23.5 hours postdose

Secondary outcomes

  1. Time-Matched Change From Baseline in QT Interval With Bazett Correction Method (QTcB) at Day 11

    QT and RR intervals will be recorded using ECG machines. QTcB will be calculated by dividing QT interval by the square root of the RR interval: QTcB = QT/RR\^1/2.

    Time frame: Time matched baseline and at multiple time-points (up to 23.5 hours) postdose on Day 11

  2. Time-Matched Change From Baseline in QT Interval With Individual Correction Method (QTcI) at Day 11

    QT and RR intervals will be recorded using ECG machines. QTcI will be calculated as QT/RR\^beta, where the value of beta will be calculated using linear regression modeling for each subject on all baseline QT - RR interval pairs.

    Time frame: Time matched baseline and at multiple time-points (up to 23.5 hours) postdose on Day 11

  3. Time-Matched Change From Baseline in Uncorrected QT at Day 11

    Time frame: Time matched baseline and at multiple time-points (up to 23.5 hours) postdose on Day 11

  4. Time-Matched Increases From Baseline in QTcF, QTcB, QTcI, and QT > 30 msec and > 60 msec at Day 11

    QTcF will be calculated by dividing QT interval by the cube root of the RR interval: QTcF= QT/RR\^1/3. QTcB will be calculated by dividing QT interval by the square root of the RR interval: QTcB = QT/RR\^1/2. QTcI will be calculated as as QT/RR\^beta, where the value of beta will be calculated using linear regression modeling for each subject on all baseline QT - RR interval pairs

    Time frame: Baseline and Day 11

  5. QTcF, QTcB, QTcI, and QT intervals >450 msec, >480 msec or >500 msec at Day 11

    QTcF will be calculated by dividing QT interval by the cube root of the RR interval: QTcF= QT/RR\^1/3. QTcB will be calculated by dividing QT interval by the square root of the RR interval: QTcB = QT/RR\^1/2. QTcI will be calculated as QT/RR\^beta., where the value of beta will be calculated using linear regression modeling for each subject on all baseline QT - RR interval pairs.

    Time frame: Day 11

  6. T-U wave complex morphology on Day 11

    Time frame: Day 11

  7. Cmax- Maximum Observed Plasma Concentration for Naltrexone, Bupropion, and their Metabolites

    Time frame: Day 11: predose and at multiple time points (up to 23.5 hours) postdose

  8. Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for Naltrexone, Bupropion, and their Metabolites

    Time frame: Day 11: predose and at multiple time points (up to 23.5 hours) postdose

  9. 9. Percentage of Participants Reporting at least one Treatment-Emergent Adverse Event (TEAE)

    Time frame: Baseline up to 30 days after the last dose of study drug

07

Study locations

1 site
  • Austin, Texas, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Jul 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2016
First posted
Apr 12, 2016
Start
Apr 2016
Primary completionActual
Jul 2016
CompletionActual
Oct 2016
Last update
Nov 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02735603
Lead sponsor
Orexigen Therapeutics, Inc
Responsible party
Sponsor
First posted
Apr 12, 2016
Start date
Apr 2016
Primary completion
Jul 2016
Completion
Oct 2016
Last update
Nov 1, 2016

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naltrexone · Bupropion · Moxifloxacin

Start the discussion